Organisation paid for research Program year 2024 Source: CMS Open Payments

Arcare 88

Neither a doctor nor a teaching hospital

Research payments

$59,148

5 payments

Through program year 2024, Arcare 88 is reported as receiving $59,148 in research payments, across 5 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$7,750	1
2023	Research	$2,500	1
2022	Research	$41,298	2
2021	Research	$7,600	1

Breakdown

Who paid Research payments · program years 2021–2024

Novartis Pharmaceuticals Corporation $59,148 5 payments

Studies the money was for Research payments · program years 2021–2024

A Randomized, Multicenter, Open-Label Trial Comparing the Effectiveness of An Inclisiran First Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (?70 MG/D $23,400 1 payment
A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (Ljn452) & Licogliflozin (Lik066) Combination Therapy, Compared to Each Monotherapy, for Treatment of Adult Patients With Nonalco $17,898 1 payment
A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (70 mg/dL) despite receiving maximally tolerated statin therapy (VICTORION-INITIATE) $10,250 2 payments
A Randomized, Multicenter, Open-Label Trial Comparing the Effectiveness of An ""Inclisiran First"" Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (?70 MG/DL) Despite Receiving Maximally Tolerated Statin Therapy (Victorion-Initiate) $7,600 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.